Lung Cancer, non small lung cancer (NSCLC)

This is the short version of onkopedia guidelines for the German-speaking countries. It focuses on algorithms for treatment in different stages with links to the evidence and its appraisal.

ICD-10 C34.-

Date of document October 2019

This document is not the most recent version. Please view: Lungenkarzinom, nicht-kleinzellig (NSCLC)

Compliance rules

Print version

Authors and societies

Authors: Frank Griesinger, Wilfried Eberhardt, Martin Früh, Oliver Gautschi, Wolfgang Hilbe, Hans Hoffmann, Rudolf Maria Huber, Sonja Loges, Christoph Pöttgen, Ron Pritzkuleit, Martin Reck, Niels Reinmuth, Martin Sebastian, Dieter Ukena, Cornelius Waller, Jürgen Wolf, Martin Wolf, Bernhard Wörmann

Previous authors: Robert Pirker, Jan Stöhlmacher, Michael Thomas

Societies

dgho oegho sghssh sgmo

1Summary

Lung cancer is the third most frequent malignancy in women and the second most frequent malignancy in men. The median age at diagnosis is between 68 and 70 years. Major risk factor is smoking.

Screening of asymptomatic high-risk persons via low-dose computer tomography (LDCT) can identify lung cancer in early stages. It reduces cancer-specific and overall mortality, especially in women.

Treatment of patients with lung cancer is paradigmatic for modern oncology. NSCLC can now be subdivided in more than a dozen biological entities with individual treatment concepts. Prognosis of patients is determined by stage, histology, immunohistochemistry, sex, ECOG status and comorbidity.

Treatment options include surgery, radiation and systemic treatment, often combined in multimodal concepts. Treatment in early stages and in some patients with advanced stage is curative. For patients in stage IIIB/IV the integration of immune checkpoint and of kinase inhibitors has significantly improved their prognosis.

2[Kapitel nicht relevant]

3[Kapitel nicht relevant]

4[Kapitel nicht relevant]

5[Kapitel nicht relevant]

6Therapy

6.1Therapeutic algorithm

6.1.1Primary therapy

Primary therapy is based on the criteria of the 8^th lung cancer TNM classification and clinical staging system, see Figure 1.

Figure 1: Algorithm for Primary Therapy

curative therapy; palliative therapy;
¹ clinical stages;
² see figure

6.1.2Systemic therapy in advanced stages

Recommendations are based on predictive, histological, immunohistochemical and genetic markers, see Figure 2.

Figure 2: Systemic therapy in advanced stages - overview

6.1.2.1Molecular genetic stratification of therapy

This chapter contains recommendations for targeted first- and second-line treatment, see Figure 3.

Figure 3: Molecular genetic stratification in advanced stages

¹no ALK¹-, ROS1¹-, EGFR¹- mutations/translocations, ALK – Anaplastic Lymphoma Kinase, ROS1 – tyrosine protein kinase ROS,EGFR – Epidermal Growth Factor Receptor, BRAFV600E – point mutation in the BRAF gene; ²other genetic aberrations – RET aberration, c-MET Exon 14 skipping mutation or MET amplification, NTRK fusions; ³UC – uncommon mutations, UC I – point mutations or duplicatios in EGFR exons 18-21, UCII – mutation T790M in EGFR exon 20 alone or in combination with other mutations, UC III – exon 20 insertions; ⁴ALKi – ALK-inhibitor: alectinib, brigatinib, ceritinib, crizotinib, lorlatinib; ⁵ROSi – ROS1-inhibitor: ceritinib, crizotinib, cabozantinib, lorlatinib; ⁶EGFR-TKI – afatinib, dacomitinib, erlotinib, gefitinib, osimertinib; ⁷dabrafenib/trametinib is approved for first and second line therapy by the EU; ⁸ CR – complete remission, PR – partial remission, SD – stable disease, PD – progressive disease; ⁹ other systemic therapy, e. g. carboplatin/paclitaxel/atezolizumab/bevacizumab; ¹⁰ see approval status;

6.1.2.2No molecular genetic stratification of therapy

The majority of patients with NSCLC does not have predictive markers for molecular stratified therapy. Immunochemotherapy has become the standard of care in the first line treatment of these patients, see Figure 4.

Figure 4: No molecular genetic stratification advanced stages

¹PD-L1 TPS – expression of PD-L1 on tumor cells, quantified by the Tumor Progression Score (TPS); ²suitable for immunotherapy with no significant contraindications; ³combination of an immune checkpoint inhibitor and histology-stratified chemotherapy; ⁴combination of cis- or carboplatin and pemetrexed; ⁵combination of carboplatin and paclitaxel or nab paclitaxel; ⁶CR – complete remission, PR – partial remission, SD – stable disease, PD – progressive disease; ⁷nintedanib only in adenocarcinoma; ⁸third generation cytostatic drugs: gemcitabine, pemetrexed, vinorelbine; pemetrexed only in non-squamous cell carcinoma; ⁹afatinib only in squamous cell carcinoma; ¹⁰PD-1/PD-L1 inhibitor: atezolizumab (independent of PD-L1 expression), nivolumab (independent of PD-L1 expression), pembrolizumab (only with TPS ≥1%); efficacy has not been demonstrated in patients who received immune checkpoint inhibitors in first line;

6.2Facts and Appraisal

6.2.1Adjuvant therapy

6.2.1.1Adjuvant chemotherapy

Adjuvant chemotherapy is recommended in patients with stages II-IIIA after surgical R0 resection. Data are summarized in Figure 5 and Figure 6.

Figure 5: Adjuvant chemotherapy in NSCLC (ANITA trial)

¹ N - number of patients; ³ DFS – disease-free survival rate after 76 months, in %; ⁴ OS – overall survival rate after 76 months, in %; ⁷ results for control, results for new therapy; ⁸ hazard ratio for new therapy;
Publication: DOI:10.1016/S1470-2045(06)70804-X

Figure 6: Adjuvant chemotherapy in NSCLC (IALT trial);

¹ N - number of patients; ² RR - remission rate, in %; ³ DFS – disease-free survival; ⁴ OS – overall survival; ⁸ hazard ratio for new therapy;
Publication: DOI:10.1200/JCO.2009.23.2272

6.2.1.2Adjuvant immunotherapy

6.2.1.2.1Durvalumab, Stage III, after radiochemotherapy

Data are summarized in Figure 7.

Figure 7: Durvalumab in NSCLC, Stage III, after radiochemotherapy

¹ N - number of patients; ² RR - remission rate, in %; ³ PFS - progression-free survival, in months; ⁴ OS – overall survival, in months; ⁵ QoL – quality of life; ⁶ SAE – serious adverse events, CTCAE grade 3/4; ⁷ results for control, results for new therapy; ⁸ hazard ratio for new therapy;
Publication DOI:10.1056/NEJMoa1709937; DOI:10.1056/NEJMoa1809697

6.2.2Advanced stages

6.2.2.1Molecular genetic stratification

6.2.2.1.1ALK inhibitors

6.2.2.1.1.1First line, molecular genetic stratification

Data are summarized in Figure 8, Figure 9 and Figure 10.

Figure 8: Alectinib in ALK+ NSCLC, first line

¹ N - number of patients; ² RR - remission rate, in %; ³ PFS - progression-free survival, in months; ⁴ OS - overall survival, in months; ⁵ QoL – quality of life; ⁶ SAE – serious adverse events, CTCAE grade 3/4; ⁷ results for control, results for new therapy; ⁸ hazard ratio for new therapy; ⁹ n. s. - not significant; ¹⁰ n. r. – median not reached;
Publication: DOI:10.1056/NEJMoa1704795

Figure 9: Ceritinib in NSCLC, ALK+, first line

Figure 10: Crizotinib in NSCLC, ALK+, first line

6.2.2.1.1.2Second line, molecular genetic stratification

Data are summarized in Figure 11, Figure 12, Figure 13 and Figure 14.

Figure 11: Alectinib in ALK+ NSCLC, second line

Figure 12: Brigatinib in NSCLC, ALK+, second line

Figure 13: Ceritinib in NSCLC, ALK+, second line

¹ N - number of patients; ² RR - remission rate, in %; ³ PFS - progression-free survival, in months; ⁴ OS - overall survival, in months; ⁵ QoL – quality of life; ⁶ SAE – serious adverse events, CTCAE grade 3/4; ⁷ results for control, results for new therapy; ⁸ hazard ratio for new therapy; ⁹ n. s. - not significant; ¹¹ pemetrexed or docetaxel
Publication: DOI:10.1016/S1470-2045(17)30339-X

Figure 14: Crizotinib in NSCLC, ALK+, second line

6.2.2.1.2BRAF inhibitors, first and second line

Data are summarized in Figure 15 and Figure 16.

Figure 15: Dabrafenib + Trametinib in NSCLC, BRAF V600E, first line

¹ N - number of patients; ² RR - remission rate, in %; ³ PFS - progression-free survival, in months; ⁴ OS – overall survival, in months; ⁵ QoL – quality of life; ⁶ SAE – serious adverse events, CTCAE grade 3/4; ⁷ results for control, results for new therapy; ⁸ hazard ratio for new therapy; ⁹ n. s. - not significant; ¹⁰ n. d. - not determined;
Publication: DOI:10.1016/S1470-2045(17)30679-4

Figure 16: Dabrafenib + Trametinib in NSCLC, BRAF V600E, second line

¹ N - number of patients; ² RR - remission rate, in %; ³ PFS - progression-free survival, in months; ⁴ OS – overall survival, in months; ⁵ QoL – quality of life; ⁶ SAE – serious adverse events, CTCAE grade 3/4; ⁷ results for control, results for new therapy; ⁸ hazard ratio for new therapy; ⁹ n. s. - not significant; ¹⁰ n. d. - not determined;
Publication: DOI:10.1016/S1470-2045(16)30146-2

6.2.2.1.3EGFR inhibitors

6.2.2.1.3.1First line, EGFR inhibitors

Data are summarized in Figure 17, Figure 18, Figure 19, Figure 20, Figure 21 and Figure 22.

Figure 17: Afatinib in EGFRmutated NSCLC, first line

¹ N - number of patients; ² RR - remission rate, in %; ³ PFS - progression-free survival, in months; ⁴ OS – overall survival, in months; ⁵ QoL – quality of life; ⁶ SAE – serious adverse events, CTCAE grade 3/4; ⁷ results for control, results for new therapy; ⁸ hazard ratio for new therapy; ⁹ n. s. - not significant; ¹⁰ n. d. - not determined; CT - chemotherapy
Publication: DOI:10.1016/S1470-2045(13)70604-1; DOI:10.1016/S1470-2045(15)00026-1; DOI:10.1016/j.cllc.2018.03.009

Figure 18: Dacomitinib in NSCLC, EGFRmut, first line

¹ N - number of patients; ² RR - remission rate, in %; ³ PFS - progression-free survival, in months; ⁴ OS – overall survival, in months; ⁵ QoL – quality of life; ⁶ SAE – serious adverse events, CTCAE grade 3/4; ⁷ results for control, results for new therapy; ⁸ hazard ratio for new therapy; ⁹ n. s. - not significant; ¹⁰ n. d. - not determined;
Publication: DOI:10.1016/S1470-2045(17)30608-3; DOI:10.1200/JCO.2018.78.7994

Figure 19: Erlotinib in NSCLC, EGFRmut, first line (OPTIMAL)

¹ N - number of patients; ² RR - remission rate, in %; ³ PFS - progression-free survival, in months; ⁴ OS – overall survival, in months; ⁵ QoL – quality of life; ⁶ SAE – serious adverse events, CTCAE grade 3/4; ⁷ results for control, results for new therapy; ⁸ hazard ratio for new therapy; ⁹ n. s. - not significant; ¹⁰ n. d. - not determined;
Publication: DOI:10.1016/S1470-2045(11)70393-X

Figure 20: Erlotinib in NSCLC, EGFRmut, first line (EURTAC)

¹ N - number of patients; ² RR - remission rate, in %; ³ PFS - progression-free survival, in months; ⁴ OS – overall survival, in months; ⁵ QoL – quality of life; ⁶ SAE – serious adverse events, CTCAE grade 3/4; ⁷ results for control, results for new therapy; ⁸ hazard ratio for new therapy; ⁹ n. s. - not significant; ¹⁰ n. d. - not determined;
Publication: DOI:10.1016/S1470-2045(11)70393-X

Figure 21: Gefitinib in NSCLC, EGFRmut, first line

¹ N - number of patients; ² RR - remission rate, in %; ³ PFS - progression-free survival, in months; ⁴ OS – overall survival, in months; ⁵ QoL – quality of life; ⁶ SAE – serious adverse events, CTCAE grade 3/4; ⁷ results for control, results for new therapy; ⁸ hazard ratio for new therapy; ⁹ n. s. - not significant; ¹⁰ n. d. - not determined;
Publication: DOI:10.1056/NEJMoa0810699; DOI:10.1200/JCO.2010.33.4235

Figure 22: Osimertinib in NSCLC, EGFRmut, first line

¹ N - number of patients; ² RR - remission rate, in %; ³ PFS - progression-free survival, in months; ⁴ OS – overall survival, in months; ⁵ QoL – quality of life; ⁶ SAE – serious adverse events, CTCAE grade 3/4; ⁷ results for control, results for new therapy; ⁸ hazard ratio for new therapy; ⁹ n. s. - not significant; ¹⁰ n. d. - not determined;
Publication: DOI:10.1056/NEJMoa1713137; DOI:10.1056/NEJMoa1913662

6.2.2.1.3.2Second line, EGFR T790M

Data are summarized in Figure 23.

Figure 23: Osimertinib in NSCLC, EGFR T790M

¹ N - number of patients; ² RR - remission rate, in %; ³ PFS - progression-free survival, in months; ⁴ OS – overall survival, in months; ⁵ QoL – quality of life; ⁶ SAE – serious adverse events, CTCAE grade 3/4; ⁷ results for control, results for new therapy; ⁸ hazard ratio for new therapy; ⁹ n. s. - not significant; ¹⁰ n. d. - not determined;
Publication: DOI:10.1056/NEJMoa1411817; DOI:10.1056/NEJMoa1612674

6.2.2.1.4ROS1 inhibitors

6.2.2.1.4.1Crizotinib, ROS1 inhibitors

Data are summarized in Figure 24.

Figure 24: Crizotinib in NSCLC, ROS1+

¹ N - number of patients; ² RR - remission rate, in %; ³ PFS - progression-free survival, in months; ⁴ OS – overall survival rate after 12 months, in%; ⁵ QoL – quality of life; ⁶ SAE – serious adverse events, CTCAE grade 3/4; ⁷ results for new therapy; ⁸ hazard ratio for new therapy;
Publication: DOI:10.1056/NEJMoa1406766

6.2.2.1.4.2Others, ROS1 inhibitors

Other kinase inhibitors like ceritinib, cabozantinib, entrectinib and lorlatinib show effectivity in ROS-1 translocated NSCLC, but are not approved in the EU.

6.2.2.2No molecular genetic stratification

6.2.2.2.1Chemotherapy

6.2.2.2.1.1First line, no molecular genetic stratification

Cytostatic drugs are the backbone of systemic therapy in these patients. Data on the selection of platin derivates are summarized in Figure 25 and Figure 26, data on pemetrexed in Figure 27.

Figure 25: Platin derivates in NSCLC, advanced stages

¹ N - number of patients; ² RR - remission rate, in %; ³ PFS - progression-free survival, in months; ⁴ OS – overall survival, in months; ⁵ QoL – quality of life; ⁶ SAE – serious adverse events, CTCAE grade 3/4; ⁷ results for control, results for new therapy; ⁸ hazard ratio for new therapy (confidence interval);
Publication: DOI:10.1002/14651858.CD009256.pub2

Figure 26: Platin derivates in NSCLC, first line

¹ N - number of patients; ² RR - remission rate, in %; ³ PFS - progression-free survival, in months; ⁴ OS – overall survival, in months, in %; ⁵ QoL – quality of life; ⁶ SAE – serious adverse events, CTCAE grade 3/4; ⁸ hazard ratio for new therapy (confidence interval); ⁹gemcitabine, vinorelbine, docetaxel, paclitaxel, irinotecan, or pemetrexed;
Publication: DOI:10.1016/j.lungcan.2019.07.010

Figure 27: Pemetrexed in NSCLC, first line

¹ N - number of patients; ² RR - remission rate, in %; ³ PFS - progression-free survival, in months; ⁴ OS – overall survival, in months, in %; ⁵ QoL – quality of life; ⁶ SAE – serious adverse events, CTCAE grade 3/4; ⁷ results for control, results for new therapy; ⁸ hazard ratio for new therapy;
Publication: DOI:10.1200/JCO.2007.15.0375

6.2.2.2.1.2Second line, no molecular genetic stratification

Data on docetaxel are summarized in Figure 28.

Figure 28: Docetaxel in NSCLC, second line

¹ N - number of patients; ² RR - remission rate, in %; ³ PFS - progression-free survival, in months; ⁴ OS – overall survival, in months, in %; ⁵ QoL – quality of life; ⁶ SAE – serious adverse events, CTCAE grade 3/4; ⁷ results for control, results for new therapy; ⁸ hazard ratio for new therapy;
Publication: DOI:10.1200/JCO.2000.18.12.2354

6.2.2.2.2Immunotherapy

Immune checkpoint inhibitors are approved as monotherapy and in combination with chemotherapy.

6.2.2.2.2.1First line, monotherapy

Data are summarized in Figure 29.

Figure 29: Pembrolizumab in NSCLC, PD-L1 ≥%, first line

¹ N - number of patients; ² RR - remission rate, in %; ³ PFS - progression-free survival, in months; ⁴ OS – overall survival, in months, in %; ⁵ QoL – quality of life; ⁶ SAE – serious adverse events, CTCAE grade 3/4; ⁷ results for control, results for new therapy; ⁸ hazard ratio for new therapy;
Publication: DOI:10.1056/NEJMoa1606774

6.2.2.2.2.2First line, combination therapy

Data are summarized in Figure 30, Figure 31 and Figure 32.

Figure 30: Atezolizumab in NSCLC, non-squamous, combination, first line

¹ N - number of patients; ² RR - remission rate, in %; ³ PFS - progression-free survival, in months; ⁴ OS – overall survival, in months, in %; ⁵ QoL – quality of life; ⁶ SAE – serious adverse events, CTCAE grade 3/4; ⁷ results for control, results for new therapy; ⁸ hazard ratio for new therapy;
Publication: DOI:10.1056/NEJMoa1716948

Figure 31: Pembrolizumab in NSCLC, non-squamous, combination, first line

¹ N - number of patients; ² RR - remission rate, in %; ³ PFS - progression-free survival, in months; ⁴ OS – overall survival, in months, in %; ⁵ QoL – quality of life; ⁶ SAE – serious adverse events, CTCAE grade 3/4; ⁷ results for control, results for new therapy; ⁸ hazard ratio for new therapy;
Publication: DOI:10.1056/NEJMoa1801005

Figure 32: Pembrolizumab in NSCLC, squamous, combination, first line

¹ N - number of patients; ² RR - remission rate, in %; ³ PFS - progression-free survival, in months; ⁴ OS – overall survival, in months, in %; ⁵ QoL – quality of life; ⁶ SAE – serious adverse events, CTCAE grade 3/4; ⁷ results for control, results for new therapy; ⁸ hazard ratio for new therapy;
Publication: DOI:10.1056/NEJMoa1810865

6.2.2.2.2.3Second line, Immunotherapy

Data are summarized in Figure 33, Figure 34, Figure 35 and Figure 36.

Figure 33: Atezolizumab in NSCLC, second line

¹ N - number of patients; ² RR - remission rate, in %; ³ PFS - progression-free survival, in months; ⁴ OS – overall survival, in months, in %; ⁵ QoL – quality of life; ⁶ SAE – serious adverse events, CTCAE grade 3/4; ⁷ results for control, results for new therapy; ⁸ hazard ratio for new therapy; ¹¹ docetaxel, pemetrexed or nivolumab;
Publication: DOI:10.1016/S0140-6736(16)32517-X

Figure 34: Nivolumab in NSCLC, non-squamous, second line

¹ N - number of patients; ² RR - remission rate, in %; ³ PFS - progression-free survival, in months; ⁴ OS – overall survival, in months, in %; ⁵ QoL – quality of life; ⁶ SAE – serious adverse events, CTCAE grade 3/4; ⁷ results for control, results for new therapy; ⁸ hazard ratio for new therapy; ¹¹ pemetrexed, gefitinib or crizotinib;
Publication: DOI:10.1056/NEJMoa1507643

Figure 35: Nivolumab in NSCLC, squamous, second line

¹ N - number of patients; ² RR - remission rate, in %; ³ PFS - progression-free survival, in months; ⁴ OS – overall survival, in months, in %; ⁵ QoL – quality of life; ⁶ SAE – serious adverse events, CTCAE grade 3/4; ⁷ results for control, results for new therapy; ⁸ hazard ratio for new therapy; ¹¹ docetaxel;
Publication: DOI:10.1056/NEJMoa1507643

Figure 36: Pembrolizumab in NSCLC, PD-L1 ≥%, second line

¹ N - number of patients; ² RR - remission rate, in %; ³ PFS - progression-free survival, in months; ⁴ OS – overall survival, in months, in %; ⁵ QoL – quality of life; ⁶ SAE – serious adverse events, CTCAE grade 3/4; ⁷ results for control, results for new therapy; ⁸ hazard ratio for new therapy; ¹¹ pemetrexed, docetaxel or nivolumab;
Publication: DOI:10.1016/S0140-6736(15)01281-7

6.2.2.2.3Others

6.2.2.2.3.1First line, others

Data are summarized in Figure 37.

Figure 37: Bevacizumab in NSCLC, non-squamous, combination, first line

¹ N - number of patients; ² RR - remission rate, in %; ³ PFS - progression-free survival, in months; ⁴ OS – overall survival, in months, in %; ⁵ QoL – quality of life; ⁶ SAE – serious adverse events, CTCAE grade 3/4; ⁷ results for control, results for new therapy; ⁸ hazard ratio for new therapy;
Publication: DOI:10.1056/NEJMoa061884

6.2.2.2.3.2Second line, others

Others including antiangiogenetic agents and tyrosine kinase inhibitors. Data are summarized in Figure 38, Figure 39, Figure 40 and Figure 41

Figure 38: Afatinib in NSCLC, squamous-cell carcinoma, first line

¹ N - number of patients; ² RR - remission rate, in %; ³ PFS - progression-free survival, in months; ⁴ OS – overall survival, in months, in %; ⁵ QoL – quality of life; ⁶ SAE – serious adverse events, CTCAE grade 3/4; ⁷ results for control, results for new therapy; ⁸ hazard ratio for new therapy; ¹¹ docetaxel;
Publication: DOI:10.1016/S1470-2045(15)00006-6

Figure 39: Erlotinib in NSCLC, EGFRmut, second line

¹ N - number of patients; ² RR - remission rate, in %; ³ PFS - progression-free survival, in months; ⁴ OS – overall survival, in months, in %; ⁵ QoL – quality of life; ⁶ SAE – serious adverse events, CTCAE grade 3/4; ⁷ results for control, results for new therapy; ⁸ hazard ratio for new therapy;
Publication: DOI:10.1056/NEJMoa050753

Figure 40: Nintedanib in NSCLC, adenocarcinoma, combination, second line

¹ N - number of patients; ² RR - remission rate, in %; ³ PFS - progression-free survival, in months; ⁴ OS – overall survival, in months, in %; ⁵ QoL – quality of life; ⁶ SAE – serious adverse events, CTCAE grade 3/4; ⁷ results for control, results for new therapy; ⁸ hazard ratio for new therapy;
Publication: DOI:10.1016/S1470-2045(13)70586-2

Figure 41: Ramucirumab in NSCLC, combination, second line

¹ N - number of patients; ² RR - remission rate, in %; ³ PFS - progression-free survival, in months; ⁴ OS – overall survival, in months, in %; ⁵ QoL – quality of life; ⁶ SAE – serious adverse events, CTCAE grade 3/4; ⁷ results for control, results for new therapy; ⁸ hazard ratio for new therapy;
Publication: DOI:10.1016/S0140-6736(14)60845-X

7[Kapitel nicht relevant]

8[Kapitel nicht relevant]

9[Kapitel nicht relevant]

10[Kapitel nicht relevant]

11[Kapitel nicht relevant]

12[Kapitel nicht relevant]

13[Kapitel nicht relevant]

14Authors' Affiliations

PD Dr. med. Wilfried Eberhardt

Universitätsklinikum Essen
Westdeutsches Tumorzentrum
Innere Klinik und Poliklinik

Hufelandstr. 55

45147 Essen

Wilfried.Eberhardt@uk-essen.de

Dr. med. Martin Früh

Kantonsspital St. Gallen
Departement Innere Medizin
Fachbereich Onkologie/Hämatologie

CH-9007 St. Gallen

martin.frueh@kssg.ch

PD Dr. med. Oliver Gautschi

Luzerner Kantonsspital
Medizinische Onkologie

CH-6000 Luzern

oliver.gautschi@luks.ch

Prof. Dr. med. Frank Griesinger

Pius Hospital Oldenburg
Universitätsklinik Innere Medizin-Onkologie
Klinik für Hämatologie und Onkologie

Georgenstr. 12

26121 Oldenburg

frank.griesinger@pius-hospital.de

Prim. Univ.-Prof. Dr. Wolfgang Hilbe

Wilhelminenspital Wien
1. Medizinische Abteilung
Zentrum für Onkologie und Hämatologie und Palliativstation

Montleartstr. 37

A-1160 Wien

wolfgang.hilbe@wienkav.at

Prof. Dr. med. Hans Hoffmann

Klinikum rechts der Isar
der Technischen Universität München
Sektion für Thoraxchirurgie

Ismaninger Str. 22

81675 München

thoraxchirurgie@mri.tum.de

Prof. Dr. med. Rudolf Maria Huber

Klinikum der Universität München-Innenstadt
Pneumologie

Ziemssenstr. 1

80336 München

huber@med.uni-muenchen.de

Prof. Dr. med. Dr. rer. nat. Sonja Loges

Medizinische Fakultät Mannheim der Universität Heidelberg
Universitätsklinikum Mannheim
III. Medizinische Klinik

Theodor-Kutzer-Ufer 1-3

68167 Mannheim

Sonja.Loges@medma.uni-heidelberg.de

Prof. Dr. med. Christoph Pöttgen

Universitätsklinikum Essen
Westdeutsches Tumorzentrum
Klinik für Strahlentherapie

Hufelandstr. 55

45147 Essen

Christoph.Poettgen@uk-essen.de

Dr. Ron Pritzkuleit

Institut für Krebsepidemiologie
Krebsregister Schleswig-Holstein

Ratzeburger Allee 160

23538 Lübeck

ron.pritzkuleit@krebsregister-sh.de

Prof. Dr. med. Martin Reck

LungenClinic Grosshansdorf GmbH
Onkologischer Schwerpunkt

Wöhrendamm 80

22927 Großhansdorf

m.reck@lungenclinic.de

Prof. Dr. med. Niels Reinmuth

Asklepios Fachkliniken München-Gauting
Thorakale Onkologie

Robert-Koch-Allee 2

82131 München-Gauting

n.reinmuth@asklepios.com

Dr. med. Martin Sebastian

Universitätsklinik Frankfurt
Medizinische Klinik II
Bereich Hämatologie/Onkologie

Theodor-Stern-Kai 7

60590 Frankfurt / Main

sebastian@med.uni-frankfurt.de

Prof. Dr. med. Dieter Ukena

Klinikum Bremen-Ost gGmbH
Klinik für Pneumologie und Beatmungsmedizin
Interdisziplinäres Lungenzentrum

Züricher Str. 40

28235 Bremen

dieter.ukena@klinikum-bremen-ost.de

Prof. Dr. med. Cornelius Waller

Universitätsklinikum Freiburg
Klinik für Innere Medizin I
Hämatologie, Onkologie und Stammzelltransplantation

Hugstetter Str. 55

79106 Freiburg

cornelius.waller@uniklinik-freiburg.de

Prof. Dr. med. Bernhard Wörmann

Amb. Gesundheitszentrum der Charité
Campus Virchow-Klinikum
Med. Klinik m.S. Hämatologie & Onkologie

Augustenburger Platz 1

13344 Berlin

bernhard.woermann@charite.de

Prof. Dr. med. Jürgen Wolf

Universitätsklinik Köln
Centrum für Integrierte Onkologie

Kerpener Str. 62

50937 Köln

juergen.wolf@uk-koeln.de

Prof. Dr. med. Martin Wolf

Klinikum Kassel
Medizinische Klinik IV
Hämatologie/Onkologie/Immunologie

Mönchebergstr. 41-43

34125 Kassel

mwolf@klinikum-kassel.de

15Disclosure of Potential Conflicts of Interest

according to the rules of the responsible Medical Societies.

Download

Reference:

Quellenangabe:

Onkopedia-Leitlinien werden kontinuierlich an den Stand des Wissens angepasst. Die jeweils gültige Version, AGB und Nutzungsbedingungen finden Sie unter www.onkopedia.com.

Für die kommerzielle Nutzung wenden Sie sich bitte an onkopedia@dgho.de.

Onkopedia guidelines are continuously adapted to the state of knowledge. The currently valid version, terms of use and general terms and conditions can be found at onkopedia-guidelines.info.

For commercial use, please contact onkopedia@dgho.de.

Compliance rules

Authors and societies

Download

Comments